Maxim raised the firm’s price target on Nutex Health (NUTX) to $50 from $45 and keeps a Buy rating on the shares. The company’s Q3 results topped estimates, with positive trends in metrics fueling its growth, the analyst tells investors in a research note. Maxim adds that the firm expects Nutex to generate $8.9M in operating cash per quarter through 2025 and believes that the company has sufficient capital to maintain current operations, even though it may raise capital to accelerate new hospital openings.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue